FINWIRES · TerminalLIVE
FINWIRES

亞洲生質燃料最新動態:受原油價格走弱影響,馬來西亞棕櫚油價格下滑,出口量也隨之下降

-- 週二,馬來西亞棕櫚油價格跟隨原油和豆油走弱的趨勢下跌,並受到印度出口和需求下降的進一步下行壓力。 馬來西亞衍生性商品交易所(Bursa Malaysia Derivatives)5月和6月原棕櫚油合約下跌2%,分別跌至每噸4418馬來西亞林吉特(1129.45美元)和4464林吉特,創下3月中旬以來的最低水準。 據道瓊斯引述Iceberg X交易員David Ng的話稱,芝加哥豆油隔夜下跌拖累了馬來西亞棕櫚油價格。 初步估計,4月前10天馬來西亞棕櫚油出貨量較上季下降30.7%至38.9%,也對價格構成壓力。 根據印度溶劑萃取協會(Solvent Extractors' Association of India)的數據顯示,印度3月棕櫚油進口量降至三個月以來的最低點,為689,462公噸,低於2月份的847,689公噸。大豆油進口量也較上季下降4%,至287,220公噸。 據《The Edge》和Trading Economics引述分析師的話稱,由於價格居高不下,印度買家下周可能仍將謹慎增購,但最終可能會增加進口,以在季節性需求到來之前囤積庫存。 隨著印尼和泰國生物燃料摻混比例的提高,馬來西亞出口競爭力預計將有所提升,因為兩國的供應量將減少。 根據馬來西亞國家通訊社(Bernama)引述投資銀行的消息報道,由於中東衝突造成的供應不確定性,儘管價格上漲,買家仍在加速囤貨,這也將繼續推動馬來西亞出口。 根據肯納格投資銀行報道,3月馬來西亞棕櫚油出口量較上月增加40.7%,儘管2月底地緣政治衝突爆發後價格飆升,但仍出現了類似的消費行為。 根據大眾投資銀行預測,由於出口依然強勁,未來兩個月馬來西亞棕櫚油庫存可能降至約200萬噸。 根據《新海峽時報》引述聯昌證券的預測,如果需求持續旺盛且產量下降,4月份馬來西亞棕櫚油庫存將從3月的230萬噸降至220萬噸。 化肥供應中斷和厄爾尼諾現象對馬來西亞棕櫚油產量構成下行風險。 根據報導,吳先生表示,這些因素可能會推高棕櫚油期貨價格,鑑於中東衝突可能帶來更多上漲空間,目前的價格回落可能只是暫時的。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB